Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity

High-rolling investors have positioned themselves bullish on Iovance Biotherapeutics IOVA, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in IOVA often signals that someone has privileged information.

Today, Benzinga's options scanner spotted 10 options trades for Iovance Biotherapeutics. This is not a typical pattern.

The sentiment among these major traders is split, with 50% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $33,000, and 9 calls, totaling $664,426.

Projected Price Targets

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.5 to $30.0 for Iovance Biotherapeutics over the last 3 months.

Analyzing Volume & Open Interest

In terms of liquidity and interest, the mean open interest for Iovance Biotherapeutics options trades today is 5949.5 with a total volume of 2,969.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Iovance Biotherapeutics's big money trades within a strike price range of $7.5 to $30.0 over the last 30 days.

Iovance Biotherapeutics Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Current Position of Iovance Biotherapeutics

• Currently trading with a volume of 8,510,544, the IOVA's price is down by -3.61%, now at $16.8.
• RSI readings suggest the stock is currently may be overbought.
• Anticipated earnings release is in 68 days.

Professional Analyst Ratings for Iovance Biotherapeutics

5 market experts have recently issued ratings for this stock, with a consensus target price of $24.4.

• Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Iovance Biotherapeutics with a target price of $22.
• An analyst from Chardan Capital persists with their Buy rating on Iovance Biotherapeutics, maintaining a target price of $34.
• Maintaining their stance, an analyst from JMP Securities continues to hold a Market Outperform rating for Iovance Biotherapeutics, targeting a price of $25.
• An analyst from Barclays persists with their Overweight rating on Iovance Biotherapeutics, maintaining a target price of $22.
• Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Iovance Biotherapeutics with a target price of $19.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Iovance Biotherapeutics, Benzinga Pro gives you real-time options trades alerts.